De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

Androdias, Géraldine, Lünemann, Jan D, Maillart, Elisabeth, Amato, Maria Pia, Audoin, Bertrand, Bruijstens, Arlette L, Bsteh, Gabriel, Butzkueven, Helmut, Ciccarelli, Olga, Cobo-Calvo, Alvaro, Derfuss, Tobias, Di Pauli, Franziska, Edan, Gilles, Enzinger, Christian, Geraldes, Ruth, Granziera, Cristina, Hacohen, Yael, Hartung, Hans-Peter, Hynes, Sinéad, Inglese, Matilde, Kappos, Ludwig, Kuusisto, Hanna, Langer-Gould, Annette, Magyari, Melinda, Marignier, Romain, Montalban, Xavier, Mycko, Marcin P, Nourbakhsh, Bardia, Oh, Jiwon, Oreja-Guevara, Celia, Piehl, Fredrik, Prosperini, Luca, Sastre-Garriga, Jaume, Sellebjerg, Finn, Selmaj, Krzysztof, Siva, Aksel, Tallantyre, Emma ORCID: https://orcid.org/0000-0002-3760-6634, van Pesch, Vincent, Vukusic, Sandra, Weinstock-Guttman, Bianca, Zipp, Frauke, Tintoré, Mar, Iacobaeus, Ellen and Stankoff, Bruno 2024. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain 10.1093/brain/awae409

PDF - Accepted Post-Print Version Download (1MB)

Abstract

The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs after disease onset is associated with a better long-term prognosis. However, the question of when and how to de-escalate or discontinue DMTs remains open and critical. This topic was discussed during an international focused workshop organized by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in 2023. The aim was to review the current evidence on the rationale for, but also the potential pitfalls of, treatment de-escalation in MS. Several clinical scenarios emerged, mainly driven by a change in the benefit-risk ratio of DMTs over the course of the disease and with aging. The workshop also addressed the issue of de-escalation by the type of DMT used and in specific situations including pregnancy and paediatric onset MS. Finally, we provide practical guidelines for selecting appropriate patients, defining de-escalation and monitoring modalities, and outline unmet needs in this field.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: https://creativecommons.org/licenses/by-nc/4.0/, Start Date: 2024-12-21
Publisher:	Oxford University Press
ISSN:	0006-8950
Date of First Compliant Deposit:	7 January 2025
Date of Acceptance:	19 December 2024
Last Modified:	07 Jan 2025 14:45
URI:	https://orca.cardiff.ac.uk/id/eprint/175079

Actions (repository staff only)

Edit Item